ENGN - Total Utang marang Modal enGene Corp
Market dynamics for enGene Holdings Inc. (ENGN) securities on the GURU.Markets platform show a debt-to-equity ratio of 0.14. The business faces colossal R&D expenses and strict regulatory oversight. Manufacturing processes and clinical trials are outsourced to third-party contractors, creating a heavy reliance on partners. The team consists of a tight-knit circle of scientists motivated by stock options and the targeted hiring of engineers.
%20-%20Rasio%20Kabeh%20Utang%20marang%20Dana%20Pribadi&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_ENGN_-_enGene-Holdings-Inc._-_All-Debt-to-Shareholders-Equity-Ratio "ENGN (enGene Holdings Inc.) riwayat Total Utang marang Modal saka 21.02.2024 nganti 01.11.2026 | 👁️GURU.Markets👁️")
Rincian analitis perusahaan enGene Holdings Inc.
- rega lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas enGene Holdings Inc.|ENGN - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal enGene Holdings Inc.|ENGN - Gunggung utang perusahaan|Utang marang nilai buku enGene|ENGN - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan enGene|Likuiditas cepet engene.com
- informasi bathi lan kelipatan valuasi:
Analisis dhasar perusahaan:enGene
enGene Holdings Inc. competes in the high-tech gene therapy sector, which is subject to stringent regulatory oversight. By analyzing the total debt-to-equity ratio, an investor assesses the organization's degree of financial leverage. This metric compares all liabilities against net assets to determine the business's reliance on borrowed funds. For a company with expensive R&D costs, a low ratio signifies resilience to liquidity crises. The market views moderate debt as a guarantee of long-term viability when developing complex patents.
Analisis pesaing enGene Holdings Inc.
Utang marang Ekuitas argenx|BioNTech Inc. - Utang Agregat marang Ekuitas|Total Utang marang Modal ABVX|ADMA (ADMA Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal PTGX (Protagonist Therapeutics)|Total Utang marang Modal immunovant.com IMVT|KNSA - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi GRFS (Grifols SA)|Adaptive Biotechnologies Corp (ADPT) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Celldex Corp|AUPH (Aurinia Pharmaceuticals) - Total Utang marang Modal|Total Utang marang Modal biocryst.com|Rasio Total Utang marang Ekuitas VERA (Vera Therapeutics)|DNTH (Dianthus Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal PHVS (Pharvaris Corp)|Koefisien Total Utang marang Modal AbCellera (ABCL)|TRML - Utang marang Ekuitas|precigen.com (PGEN) - Rasio Total Utang marang Ekuitas|Pharming Group (PHAR) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Nektar Therapeutics Inc|Rasio Total Utang marang Ekuitas UPB|Total Utang marang Modal Zenas Corp|Utang marang Ekuitas Immunome, Inc. (IMNM)|gossamerbio.com - Rasio Utang marang Ekuitas|Total Utang marang Modal KALV (KalVista Pharmaceuticals, Inc.)|Septerna, Inc. (SEPN) - Utang marang Modal|Pieris Pharmaceuticals Inc - Total Utang marang Modal|Utang marang Modal Savara Pharma|Rigel Pharmaceuticals (RIGL) - Utang marang Ekuitas|Rasio Utang marang Ekuitas ANAB|ATXS (Astria Therapeutics, Inc.) - Total Utang marang Modal|RAPT - Rasio Utang marang Modal|Total Utang marang Modal JBIO|ACRS - Utang marang Modal|Utang marang Ekuitas Kyverna Therapeutics KYTX|TLSA: Rasio Utang marang Ekuitas|Cabaletta Bio - Total Utang marang Modal|Utang marang Modal Ventyx Biosciences Inc.|THTX (Theratechnologies Inc) - Rasio Total Utang marang Ekuitas|Avalo Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|ELDN (Eledon Pharmaceuticals) - Total Utang marang Modal|AGEN: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Climb Bio (CLYM)|ZURA - Utang marang Modal|Utang marang Ekuitas aTyr ATYR|Adagene Inc - Utang marang Ekuitas|Ikena Oncology, Inc. - Total Utang marang Modal|STTK (Shattuck Labs, Inc.) - Rasio Utang marang Ekuitas|EQ: Total Utang marang Modal|CNTB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Immunic Therapeutics|Rasio Utang marang Ekuitas ATRA (Atara Biotherapeutics Inc)|Total Utang marang Modal IFRX|x4pharma.com (XFOR) - Rasio Utang marang Modal|Utang marang Ekuitas Adicet Bio, Inc. ACET|Koefisien Total Utang marang Modal Celularity Inc (CELU)|INMB: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi BRNS (Barinthus Biotherapeutics Corp)|KZR: Total Utang marang Modal|SABS - Koefisien Total Utang marang Modal|Utang marang Ekuitas Akari Therapeutics Plc|Rasio Utang marang Ekuitas ENLV (Enlivex Therapeutics, Ltd.)|Total Utang marang Modal QTTB|Rasio Total Utang marang Ekuitas GeoVax Corp GOVX|Edesa Biotech, Inc. - Rasio Total Utang marang Ekuitas|Koefisien Total Utang marang Modal ibioinc.com (IBIO)|Carisma Tx - Total Utang marang Modal|Utang marang Modal XTL Biopharmaceuticals Ltd|boltbio.com (BOLT) - Utang marang Ekuitas|Rasio Utang marang Ekuitas HCWB|APVO (Aptevo Therapeutics, Inc.) - Total Utang marang Modal|AIM - Rasio Utang marang Modal|Utang marang Ekuitas Aditxt (ADTX)|GRI Bio Inc - Rasio Utang marang Ekuitas|Utang marang Ekuitas XORTX XRTX|HIND (Vyome Therapeutics) - Utang Agregat marang Ekuitas|Revelation Biosciences - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi INDP (indaptusrx.com)|SCNI: Total Utang marang Modal|CalciMedica (CALI) - Total Utang marang Modal|Utang marang Ekuitas Affimed NV|ALLK: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas HOOKIPA Pharma Inc. (HOOK)|Rasio Total Utang marang Ekuitas igmbio.com IGMS|Total Utang marang Modal ITOS (iTeos Therapeutics, Inc.)|Total Utang marang Modal Ocean Biomedical Inc OCEA|TCBP: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi THRD (Third Harmonic Bio Inc)